Nereid Therapeutics utilizes proprietary technologies to measure and visualize liquid-liquid phase separation (LLPS) in mammalian cells, enabling the discovery of small molecules that can modulate protein interactions involved in diseases like cancer and inflammatory disorders. By providing precise insights into biomolecular condensates, the company addresses the challenge of developing effective treatments for intractable diseases that have limited therapeutic options.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including cancers, neurodegenerative illnesses, and inflammatory disorders, are linked to the formation and function of membrane-less compartments within cells via intracellular liquid-liquid phase separation (LLPS). However, there has been no systematic method to measure intracellular LLPS and determine the impact of therapeutics on this process.
Solution
Nereid Therapeutics is developing therapies by measuring and modulating intracellular LLPS. The company utilizes technologies to illuminate the formation and behavior of biomolecular condensates, enabling the precise measurement of LLPS in mammalian cells. Combined with proprietary microscopy and computer vision, Nereid discovers small molecules that can modulate protein interactions found in disease states. The company's platform integrates soft matter physics, cell biology, machine learning, and medicinal chemistry to discover therapeutics that can modify the phase behavior of living cells.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing treatments for cancers, neurodegenerative illnesses, and inflammatory disorders.
Features
- Proprietary technologies to measure and visualize LLPS in mammalian cells
- Advanced microscopy and computer vision to illuminate the formation and behavior of biomolecular condensates
- Discovery of small molecules that modulate protein interactions in disease states
- Platform integrates soft matter physics, cell biology, machine learning, and medicinal chemistry